THE EFFECTS OF RENAL DENERVATION ON DYNAMICS OF BIOCHEMICAL INDICATORS OF VASCULAR FIBROSIS IN PATIENTS WITH RESISTANT HYPERTENSION

In recent years, an increasing attention is paid to the development of vascular fibrosis in patients with arterial hypertension (AH). Particular importance is given to changes in the concentrations of matrix metalloproteinases (MMPs), which play a key role in the development of connective tissue disorders. As of today, research data on the levels of the MMP(2 and the MMP(9 in hypertensive patients and their changes due to treatments remain controversial. Data concerning the impact of renal sympathetic denervation on the changes in the MMPs concentrations in patients with resistant hypertension are unavailable. The objectives of the study were (1) to determine the contents of matrix metalloproteinases 2 and 9 and of their tissue inhibitor TIMP(1 in patients with resistant hypertension before and 6 months after the transcatheter renal artery sympathetic denervation; (2) to compare these parameters in cases of effective and ineffective invasive treatment; and (3) to study the interaction between the enzymes concentrations and blood pressure levels, including pulse pressure levels. 

1. Аксененко М.Б. Матриксная металлопротеиназа-9 как потенциальная молекулярная мишень для терапии меланомы кожи // Сибирск. онкологический журн. – 2011. – Приложение № 1. – С. 8–9.

2. Мазовка К.Е., Ткачев А.В. Экспрессия матриксной металлопротеиназы(9 и тканевого ингибитора матриксной металлопротеиназы(1 в слизистой оболочке кишечника у больных с воспалительными заболеваниями кишечника в зависимости от активности заболевания // Практ. медицина. – 2014. – Т. 1(77). – С. 53–56.

3. Павлюченко К.П., Олейник Т.В., Коробова А.В. Изменение уровней металлопротеиназы-9, ее тканевого ингибитора и цитокинов у больных сахарным диабетом 2-го типа: 1 год наблюдения // Таврический медикобиологический вестн. – 2012. – Т. 15, № 3, ч. 3(59). – С. 117–120.

4. Рогова Л.Н., Шестернина Н.В., Замечник Т.В. и др. Матриксные металлопротеиназы, из роль в физиологических и патологических процессах (обзор) // Вестн. новых мед. технологий. – 2011. – Т. 18, № 2. – С. 86–89.

5. Соболева Г.М., Сухих Г.Т. Семейство матриксных металлопротеиназ: общая характеристика и физиологическая роль // Акуш. и гин. – 2007. – № 1. – С. 5–8.

6. Труфанов К.В., Ракита Д.Р., Вулех В.М. и др. Прогностическое значение матриксной металлопротеиназы-9 для развития ремоделирования левого желудочка в госпитальном периоде острого инфаркта миокарда // Рос. медикобиолог. вестн. им. акад. И.П. Павлова. – 2012. – № 4. – C. 87–91.

7. Dart A.M. Pulse pressure – a review of mechanisms and clinical relevance // J. Am. Coll. Cardiol. – 2001. – Vol. 37. – P. 975– 984.

8. DeLeon(Pennell K.Y., Tian Y., Zhang B. et al. CD36 Is a Matrix Metalloproteinase(9 Substrate that Stimulates Neutrophil Apoptosis and Removal during Cardiac Remodeling // Circ. Cardiovasc. Genet. – 2015. – P. 14–25.

9. Evrosimovska B., Velickovski В., Dimova C. et al. Matrix metalloproteinases (with accent to collagenases) // J. Cell Anim. Biol. – 2011. – Vol. 5(7). – Р. 113–120.

10. Fana X.Z., Zhu H.J., Wu X. et al. Effects of doxycycline on cx43 distribution and cardiac arrhythmia susceptibility of rats after myocardial infarction // Iran J. Pharm. Res. – 2014. – Vol. 13(2). – P. 613–621.

11. Fontana V., Silva P.S., Gerlach R.F., Tanus(Santos J.E. Circulating matrix metalloproteinases and their inhibitors in hypertension // Clin. Chim. Acta. – 2012. – Vol. 413(7–8). – P. 656–662.

12. Intengan H.D., Schiffrin E.L. Structure and Mechanical Properties of Resistance Arteries in Hypertension. Role of Adhesion Molecules and Extracellular Matrix Determinants // Hypertension. – 2000. – Vol. 36(3). – P. 312–318.

13. Jefferis B.J., Whincup P., Welsh P. et al. Prospective study of matrix metalloproteinase(9 and risk of myocardial infarction and stroke in older men and women // Atherosclerosis. – 2010. – Vol. 208(2). – P. 557–563.

14. Lindsay M.M., Maxwell P., Dunn F.G. TIMP-1 A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension // Hypertension. – 2002. – Vol. 40. – P. 136–141.

15. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. – 2006. – Vol. 1(11). – P. 1696–1701.

16. Mason D.P., Kenagy R.D., Hasenstab D. et al. Matrix metalloproteinase(9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery // Circulation Research. – 1999. – Vol. 85(12). – P. 1179–1185.

17. Onal I.K., Altun B., Onal E.D. et al. Serum levels of MMP(9 and TIMP(1 in primary hypertension and effect of antihypertensive treatment // Eur. J. Intern. Med. – 2009. – Vol. 20(4). – P. 369– 372.

18. Pender S.L., Tickle S.P., Docherty A.J. et al. A major role for matrix metalloproteinases in T cell injury in the gut // Immunol. – 1997. – Vol. 158. – Р. 1582–1590.

19. Safar M.E., Bernard M.D., Levy I. et al. Current Perspectives on Arterial Stiffness and Pulse Pressure in Hypertension and Cardiovascular Diseases // Circulation. – 2003. – Vol. 107. – P. 2864–2869.

20. Tayebjee M.H., Nadar S., Blann A.D. et al. Matrix metalloproteinase(9 and tissue inhibitor of metalloproteinase( 1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo(Scandinavian Cardiac Outcomes Trial (ASCOT) // Am. J. Hypertens. – 2004. – Vol. 17(9). – P. 764–769.

21. Thiennu H.V., Zena W. Matrix metalloproteinases: effectors of development and normal physiology // Genes & Development. – 2000. – Vol. 14. – P. 2123–2133.

22. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology // Genes & Development. – 2000. – Vol. 14(17). – P. 2123–2133.

23. Yasmin, McEniery C.M., Wallace S., Dakham Z. et al. Matrix metalloproteinase(9 (MMP(9), MMP(2, and serum elastase activity are associated with systolic hypertension and arterial stiffness // Arteriosclerosis, Thrombosis and Vascular Biology. – 2005. – Vol. 25(2). – P. 372.

24. Zervoudaki A., Economou E., Stefanadis C. et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment // J. Human Hypertension. – 2003. – Vol. 17. – P. 119–124.

25. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness // Arteriosclerosis, Thrombosis and Vascular Biology. – 2005. – Vol. 25. – P. 932–943.